Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Rain
Toggle navigation
Menu
Subscribe
Home
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
206.14
USD
+3.79 (+1.87%)
Official Closing Price
Updated: 7:58 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
88
89
Next >
Lilly Completes Acquisition of Prevail Therapeutics
January 22, 2021
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery...
From
PR Newswire
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
January 21, 2021
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The...
From
PR Newswire
Thinking about trading options or stock in General Motors, Eli Lilly, CarMax, Micron Technology, or Roku?
January 20, 2021
InvestorsObserver issues critical PriceWatch Alerts for GM, LLY, KMX, MU, and ROKU.
From
PR Newswire
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies,...
From
PR Newswire
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
January 15, 2021
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the...
From
PR Newswire
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
January 15, 2021
Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts
From
PR Newswire
Gabrielle Sulzberger Elected to Lilly Board of Directors
January 14, 2021
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member of Lilly's board, she will serve on both the Audit...
From
PR Newswire
Thinking about trading options or stock in Blink Charging, Tesla, WW International, Inmode, or Eli Lilly?
January 12, 2021
InvestorsObserver issues critical PriceWatch Alerts for BLNK, TSLA, WW, INMD, and LLY.
From
PR Newswire
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
January 12, 2021
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic,...
From
PR Newswire
Thinking about trading options or stock in Eli Lilly, Gilead Sciences, GameStop, Boeing, or Roku?
January 11, 2021
InvestorsObserver issues critical PriceWatch Alerts for LLY, GILD, GME, BA, and ROKU.
From
PR Newswire
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
January 11, 2021
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the...
From
PR Newswire
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
January 11, 2021
Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients...
From
PR Newswire
Further Research into Psilocybin Opens New Doors for Treatment
January 07, 2021
FinancialBuzz.com News Commentary
From
PR Newswire
(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?
January 05, 2021
From
GlobeNewswire News Releases
Lilly to Participate in J.P. Morgan Healthcare Conference
January 04, 2021
Eli Lilly and Company (NYSE:LLY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. David A. Ricks, Lilly's chairman and chief executive officer, will...
From
PR Newswire
(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?
December 22, 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Prevail Therapeutics Inc. ("Prevail" or the "Company") (NASDAQ: PRVL) breached their...
From
PR Newswire
Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention
December 21, 2020
BLAZE-2 Study of bamlanivimab in COVID-19 is currently underway, among residents and staff of skilled nursing or assisted living facilities
From
PR Newswire
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
December 18, 2020
Study will provide real-world data and insight on various infusion setting experiences
From
PR Newswire
PREVAIL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prevail Therapeutics Inc. - PRVL
December 16, 2020
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Prevail Therapeutics Inc. (NasdaqGS: PRVL) to...
From
PR Newswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
December 16, 2020
From
GlobeNewswire News Releases
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
December 16, 2020
From
GlobeNewswire News Releases
Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
December 15, 2020
- Lilly expects to deliver strong financial and operational performance in 2021, highlighted by volume-based revenue growth, operating margin expansion, pipeline advancements and solid cash flow.
From
PR Newswire
Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address...
From
PR Newswire
Lilly Announces 15 Percent Dividend Increase
December 14, 2020
The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2021 will be $0.85 per share on...
From
PR Newswire
Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study
December 14, 2020
- New IDEAS study will focus on African American and Latino participants
From
PR Newswire
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
December 11, 2020
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial...
From
PR Newswire
Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®
December 09, 2020
Pre-planned primary outcome analysis continues to show clinically significant improvement in invasive disease-free survival as data mature for people with HR+, HER2- high risk early breast cancer
From
PR Newswire
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
December 09, 2020
More than half of participants taking the highest dose achieved normal A1C levels, a key secondary endpoint in first phase 3 trial of SURPASS program
From
PR Newswire
Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement
December 08, 2020
Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2021 on Tuesday, December 15, 2020. Lilly will also conduct a conference call on that day with the investment community and...
From
PR Newswire
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology
December 07, 2020
62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or...
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
88
89
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.